Beta Bionics, Inc. cash flow to debt ratio of -697.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Beta Bionics, Inc.'s free cash flow has decreased 8.81% from $-51.67M last year to $-56.22M, signaling decreasing performance

Beta Bionics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Beta Bionics, Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.03 today, signaling strengthened financials

Beta Bionics, Inc. has negative EBITDA, making leverage ratio unreliable

Beta Bionics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Beta Bionics, Inc.'s profit margin has increased (-28.32%) in the last year from -84.08% to -60.27%, signaling increasing performance

Beta Bionics, Inc.'s short-term assets of $267.90M exceed its short-term liabilities of $30.92M

Beta Bionics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Beta Bionics, Inc.'s return on equity of -23.00%, is lower than 15.00%, indicating bad performance

Beta Bionics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Beta Bionics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Beta Bionics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Beta Bionics, Inc. has negative free cash flow, indicating cash burn

Beta Bionics, Inc.'s yearly earnings has decreased 33.68% since last year from $-54.76M to $-73.20M, signaling decreasing performance

Beta Bionics, Inc.'s yearly revenue has increased 53.94% since last year from $65.12M to $100.25M, signaling increasing performance

ROIC -27.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Beta Bionics, Inc.'s 3-year revenue CAGR of 724.29% is positive, indicating growing revenue over the past 3 years

Beta Bionics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Beta Bionics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Beta Bionics, Inc. has insufficient data to evaluate this check.

Beta Bionics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Beta Bionics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Beta Bionics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Beta Bionics, Inc. has insufficient data to evaluate this check.

Beta Bionics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Beta Bionics, Inc. has a price-to-book ratio of 2.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Beta Bionics, Inc. has a price-to-sales ratio of 6.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue